Obesity Awareness

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials.

AT A GLANCE DaVita Inc. issued a statement in response to Novo Nordisk in relation ‘…to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease (CKD) and lowers the risk of kidney and cardiovascular mortality.’ Retatrutide, an Eil Lilly drug yet to be approved by the FDA, boasting ‘…Phase 2 trial results […]

DaVita challenged by GLP-1 outcomes for kidney disease; the stock market is getting Ozempic’ed; more employers end GLP-1 coverage; under-representation of people with obesity in clinical trials. Read More »

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day.

Hello all, It continues to be a fascinating, rapid and intense period of development in obesity and metabolic medicine. We learn something new virtually every week; we are very much looking forward to Obesity Week in Dallas, TX and the latest developments in evidence-based obesity science and treatments. In this Weekly Roundup, we have interesting articles including Novo

Compounded GLP-1 meds, chronic kidney disease outcomes, Walmart woes, and World Pet Obesity Awareness Day. Read More »

Let’s do right and SELECT the best for our patients suffering from obesity.

Let’s do right and SELECT the best for our patients suffering from obesity.

Hello everyone, I hope you are all enjoying this weekend in good health. Here at twenty30 health, our hearts go out to everyone impacted by the wildfires in Maui, and we share in the sense of tragedy and horror at these terrible events. Our focus of this newsletter is the onward media and corporate hype around GLP-1

Let’s do right and SELECT the best for our patients suffering from obesity. Read More »

The WeightWatchers gamble; employers crackdown on GLP-1s; patients sabotaged by their own physicians; and racism and obesity in our adolescents.

The WeightWatchers gamble; employers crackdown on GLP-1s; patients sabotaged by their own physicians; and racism and obesity in our adolescents.

Hello everyone, I hope you are enjoying this weekend!  It has been a week of sunshine — and heat! And humidity, and allergies, in the Northeast this week. It was also a week where we were able to convene our growing twenty30health team in Philadelphia, the cradle of so much emerging healthcare innovation. What a

The WeightWatchers gamble; employers crackdown on GLP-1s; patients sabotaged by their own physicians; and racism and obesity in our adolescents. Read More »

Access, affordability and adherence issues with GLP-1 meds; outcomes beyond weight loss to enhance cardiovascular health; AI for obesity management

Access, affordability and adherence issues with GLP-1 meds; outcomes beyond weight loss to enhance cardiovascular health; AI for obesity management?

Hello everyone, I hope you are enjoying the weekend, and trust you enjoyed the fireworks, summer sunshine and celebrations of American Independence Day this past week. It was a slower news week in the obesity management space, perhaps a function of summer vacations — we are taking ours’ this week — but the growing focus

Access, affordability and adherence issues with GLP-1 meds; outcomes beyond weight loss to enhance cardiovascular health; AI for obesity management? Read More »

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity!

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity!

AT A GLANCE Ozempic to be covered by the UK National Health Service under a £40 million two-year pilot, with commentary from Prime Minister Rishi Sunak. CNN reports on the Ozempic frenzy sweeps China, with local firms developing generic versions of semaglutide. GLP-1 drugs, addiction and desire are covered in The New York Times. It’s not just humans; 59% of dogs and 61% of cats

Obesity meds and affordability; Ozempic covered by NHS in the UK and becomes a frenzy in China; GLP-1s, addiction and desire; and pets with obesity! Read More »

Scroll to Top
Skip to content